newsroom.csl.comCSL Global Newsroom

Global Selector Newsroom Partnering Contact We Are CSL We Are CSL Our Businesses and Products CSL Behring CSL Seqirus CSL Vifor Vita: Original Stories Our Leadership Worldwide Locations Corporate Governance Code of Responsible Business Practice Core Policies Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health. Read the Stories CSL consists of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor. Learn more by visiting each section. Our Businesses and Products PatientsPublic Health PatientsPublic Health RareSerious Diseases Immunodeficiency and Autoimmune Diseases Hereditary Bleeding Disorders Hereditary Angioedema Alpha 1 Antitrypsin Deficiency Iron Deficiency Iron Deficiency Patient Stories Nephrology Nephrology Patient Stories Vaccines Pandemic Response In-Licensing Antivenoms and Q fever Vaccine Patient SupportOrganizations Patient SupportOrganizations CSL Behring USA SupportAssistance Programs CSL Vifor Managed Access Programs LEAD Grants Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry. CSL Behring: RareSerious Diseases Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine companies. CSL Seqirus: Vaccines RD RD RD Capabilities Awards, Grants and Initiatives World-Class RD Network Product Pipeline Clinical Studies at CSL Current Clinical Trials Research Practices How to Participate Clinical Studies FAQs RD focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology. RD Capabilities One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world. Awards, Grants and Initiatives Sustainability Sustainability Environment Climate Resilience Energy and Emissions Waste, Water and Packaging Social Product SafetyQuality Innovation and RD AccessHealth Security ResponsibleResilient Supply Chain Sustainable Workforce Providing A Positive Working Environment Health, SafetyWellbeing Diversity, EquityInclusion Governance EthicsTransparency Data ProtectionPrivacy Stakeholder EngagementMaterial Topics Data and Reporting Centre Annual Publications Policies Key Performance Data Summary As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030. Learn About Our Targets Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy. Supporting Our Communities Careers Careers Diversity, EquityInclusion How CSL Supports Your Well-being Early Careers at CSL Apprenticeships Internships at CSL Graduate Rotational Programs at CSL At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out. Read About Our DEI Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future! Early Careers at CSL Investors One CSL Back Search Popular search terms: Clinical Trials Careers at CSL Watch: Protecting Yourself from COVID-19 and Flu Our Products We Are CSL We Are CSL Our Businesses and Products Our Businesses and Products CSL Behring CSL Plasma CSL Seqirus CSL Vifor Vita: Original Stories Our Leadership Worldwide Locations Corporate Governance Corporate Governance Code of Responsible Business Practice Core Policies PatientsPublic Health PatientsPublic Health RareSerious Diseases RareSerious Diseases Immunodeficiency and Autoimmune Diseases Hereditary Bleeding Disorders Hereditary Angioedema Alpha 1 Antitrypsin Deficiency Iron Deficiency Iron Deficiency Iron Deficiency Patient Stories Nephrology Nephrology Nephrology Patient Stories Vaccines Vaccines Pandemic Response In-Licensing Antivenoms and Q fever Vaccine Patient SupportOrganizations Patient SupportOrganizations LEAD Grants RD RD RD Capabilities Awards, Grants and Initiatives World-Class RD Network Product Pipeline Clinical Studies at CSL Clinical Studies at CSL Current Clinical Trials Research Practices How to Participate Clinical Studies FAQs Sustainability Sustainability Environment Environment Climate Resilience Energy and Emissions Waste, Water and Packaging Social Social Product SafetyQuality Innovation and RD AccessHealth Security ResponsibleResilient Supply Chain Sustainable Workforce Sustainable Workforce Providing A Positive Working Environment Health, SafetyWellbeing Diversity, EquityInclusion Governance Governance EthicsTransparency Data ProtectionPrivacy Stakeholder EngagementMaterial Topics Data and Reporting Centre Data and Reporting Centre Annual Publications Policies Key Performance Data Summary Careers Careers Diversity, EquityInclusion How CSL Supports Your Well-being Early Careers at CSL Early Careers at CSL Apprenticeships Internships at CSL Graduate Rotational Programs at CSL Investors Newsroom Partnering Contact Global Selector Global Newsroom CSL Behring Patient Zahra Khan, living with hereditary angioedema CSL Global Newsroom Global Newsroom How Can We Help You? Media Resources Media Contacts Recent News Releases Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor. Email Alerts CSL Apr 17, 2024 Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build Australia’s next CSL” Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO. Read more news from CSL Recent News Releases Email Alerts CSL Behring Jan 16, 2024 Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024... Read more news from CSL Behring Recent News Releases Email Alerts CSL Seqirus May 1, 2024 CSL Seqirus and ARS Pharma sign agreement to commercialise neffy™ (adrenaline nasal spray) in Australia and New Zealand Under the licensing and distribution agreement, CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialisation of neffyTM (adrenaline nasal spray) ARS... Read more news from CSL Seqirus Recent News Releases Email Alerts CSL Vifor Apr 24, 2024 CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically... Read more news from CSL Vifor Read all company news releases Media Resources Quick Links Fact Sheet Annual Reports CSL Leadership Leadership Perspectives CSL History Photos and Logos Videos Media Contacts CSL Victoria, Australia Phone: +61 450 909 211 Email: media@csl.com.au CSL Behring North America Email: MediaNorthAmerica@cslbehring.com Europe Email: MediaEurope@cslbehring.com Asia Pacific Email: MediaAsiaPacific@cslbehring.com CSL Seqirus EMEA and Latam Emmanuella Dekonor Phone: +44 7920500496 Email: Emmanuella.Dekonor@seqirus.com North America Tiffany Cody Phone: +1 908 370 1863 Email:...